{"autoimmune colitis": 216.81, "autoimmune hepatitis": 20.36, "colitis": 23.44, "diabetes mellitus": 2.25, "febrile neutropenia": 2.81, "general physical health deterioration": 4.66, "hepatitis": 12.41, "hyperthyroidism": 21.03, "hypophysitis": 60.58, "hypothyroidism": 15.47, "hypoxia": 4.82, "immune-mediated enterocolitis": 16.64, "immune-mediated lung disease": 25.69, "intentional product use issue": 16.58, "interstitial lung disease": 6.38, "liver disorder": 2.57, "maligt neoplasm progression": 20.05, "metastases to central nervous system": 12.76, "myocarditis": 2.85, "myositis": 12.73, "neoplasm progression": 3.21, "neuropathy peripheral": 2.52, "neutrophil count decreased": 2.74, "off label use": 2.52, "pemphigoid": 8.24, "pleural effusion": 3.5, "pneumonitis": 17.94, "product use in unapproved indication": 2.34, "rash maculo-papular": 2.67, "respiratory failure": 2.01, "sepsis": 2.29, "thyroiditis": 18.18, "transaminases increased": 2.51, "tubulointerstitial nephritis": 11.25, "tumour pseudoprogression": 71.33}